Data Sheet 1_Detection and prognostic role of circulating cancer-associated fibroblasts in

A 2026 pilot study by Kim-Lea Reese Ryterski analyzed blood samples from 31 melanoma patients (stage IIB–IV). It reports the incidence and concentration of circulating cancer-associated fibroblasts (cCAFs) and circulating tumor cells (CTCs), and their potential prognostic value when combined with lactate dehydrogenase (LDH) or S100B protein levels. The data likely contains cell counts and associated clinical outcomes for these patients.

Use Cases

• Assessing the prognostic value of circulating cancer-associated fibroblast (cCAF) counts for progression-free survival in melanoma.
• Comparing the detection rates and concentrations of cCAFs versus circulating tumor cells (CTCs) in patient blood samples.
• Evaluating risk stratification models by combining cCAF counts with established biomarkers like lactate dehydrogenase (LDH) or S100B protein levels.

Strengths

• Includes data from 31 melanoma patients with defined disease stages (IIB–IV).
• Reports specific cell count ranges (cCAFs: 1–60, mean 11; CTCs: 1–20, mean 4.5) and associated survival statistics.
• Published under a permissive CC-BY-4.0 license for reuse.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• The dataset is small (478.9 KB), reflecting a pilot study that requires validation on a larger cohort.
• Description metadata is limited; actual data quality and structure require manual inspection of the DOCX file.

Provenance

Source

figshare, author Kim-Lea Reese Ryterski.

Collection Method

Cells were enriched from whole blood samples using the CTCeptor system (automated density-based enrichment and CD45-based negative depletion) and identified via immunofluorescence staining.

Freshness

Last updated 2026-06-01 05:24:37; freshness should be verified.